Gubra (GUBRA) Stock Overview
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GUBRA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gubra A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 391.80 |
| 52 Week High | DKK 557.50 |
| 52 Week Low | DKK 293.00 |
| Beta | 0.32 |
| 1 Month Change | 10.80% |
| 3 Month Change | 15.24% |
| 1 Year Change | 5.04% |
| 3 Year Change | 261.17% |
| 5 Year Change | n/a |
| Change since IPO | 256.18% |
Recent News & Updates
Narrative Update • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.
New Narrative • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?Recent updates
Narrative Update • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.New Narrative • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?Narrative Update • Jun 24
GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.Narrative Update • Jun 10
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.Narrative Update • May 26
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analysis Article • May 14
Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...Narrative Update • Apr 27
GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).Narrative Update • Apr 12
GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).Narrative Update • Mar 29
GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).Narrative Update • Mar 15
GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.Narrative Update • Mar 01
GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).Narrative Update • Aug 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.Analysis Article • Jun 28
Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...New Narrative • May 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.Analysis Article • May 04
We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Mar 11
Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...Analysis Article • Jan 14
We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Jun 19
Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...Analysis Article • Mar 07
Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...Shareholder Returns
| GUBRA | DK Life Sciences | DK Market | |
|---|---|---|---|
| 7D | 5.4% | 4.5% | 0.7% |
| 1Y | 5.0% | 5.8% | -1.5% |
Return vs Industry: GUBRA matched the Danish Life Sciences industry which returned 5.8% over the past year.
Return vs Market: GUBRA exceeded the Danish Market which returned -1.5% over the past year.
Price Volatility
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 6.6% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 7.5% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: GUBRA's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: GUBRA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 330 | Markus Rohrwild | www.gubra.dk |
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology.
Gubra A/S Fundamentals Summary
| GUBRA fundamental statistics | |
|---|---|
| Market cap | DKK 6.43b |
| Earnings (TTM) | -DKK 182.25m |
| Revenue (TTM) | DKK 271.02m |
23.7x
P/S Ratio-35.3x
P/E RatioIs GUBRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUBRA income statement (TTM) | |
|---|---|
| Revenue | DKK 271.02m |
| Cost of Revenue | DKK 66.97m |
| Gross Profit | DKK 204.05m |
| Other Expenses | DKK 386.30m |
| Earnings | -DKK 182.25m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Mar 03, 2027
| Earnings per share (EPS) | -11.10 |
| Gross Margin | 75.29% |
| Net Profit Margin | -67.25% |
| Debt/Equity Ratio | 0% |
How did GUBRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/23 04:32 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gubra A/S is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |